Advertisement


Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opening Session Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Advertisement